Alan Tan, MD, discusses potential biomarkers that are being investigated to optimize treatment of patients with renal cell ...

Alfred L. Garfall, MD, emphasizes the critical importance of the National Institutes of Health funding for biomedical research.

The FDA has approved 2 biosimilars, denosumab-bmwo (CT-P41; Stoboclo) and (Osenvelt), for all indications of their respective reference products (Prolia) and (Xgeva), Celtrion stated in a news release ...

Tislelizumab plus chemotherapy is now FDA-approved for metastatic esophageal squamous cell carcinoma with a tumor PD-L1 ...